Morchella Medical develops and licenses the intellectual property, technology and know-how behind optimized, automated dosing, including when an AI agent sets the dose. We provide the methods, models and evidence that let companies bring it to patients safely.
The newest therapies work only as well as the way each dose is optimized and managed over time: the right starting dose, careful titration, keeping each patient within their therapeutic window, side-effect management, long-term optimization, and the safe combination of treatments.
The scale is already clear. More than a billion people live with obesity, and GLP-1 therapy has brought millions into treatment. Yet more than half discontinue within the first year, often driven by side effects and the absence of careful, individualized titration and management around the molecule.
Care around the molecule is automating from the edges inward. Fulfillment went first, then monitoring. The dose is the last manual step. As care moves to the patient and runs increasingly through software, the pathway around the molecule is what decides whether a therapy works. And when software sets the dose, someone has to be able to show why.
Adjusting a therapy to the individual is a method of treatment, and that is what our core claims cover. They were filed before anyone was building agents to do it, and they hold regardless of what sets the dose.
Our core GLP-1 patents are granted in the United States and key territories as method-of-treatment claims, structurally akin to pharmaceutical regimen patents. The claims extend from optimized dosing to dynamic dosing alongside co-therapies, and to doing this rigorously when software and AI sit in the clinical loop. Together they cover a defensible layer of how modern therapies are dosed and managed.
Automation does not remove the dosing problem. It industrializes it. A system treating a million patients needs formal, individual-level methods where a clinician could improvise, and it has to hold each patient inside their therapeutic window without a clinician watching.
Our patents span therapeutic areas and the clinical-AI safety layer, including:
New regulatory frameworks for clinically acting software are being written now. They converge on the same demands: systems that constrain themselves, that record what they did, and that can show why they did it.
Those are the demands our IP was built to answer. It is why the estate reaches past dosing methods into the architecture around them, and why the companies moving fastest on automated care are the ones these demands will reach first.
The estate is underpinned by the technology and know-how that enables our partners: clinically grounded PK/PD and machine-learning dosing models, backed by real clinical data, and working software modules developed and refined over years.
We partner with pharmaceutical and biotech developers, telehealth and direct-to-patient platforms, and clinical-AI providers.
We provide the IP, evidence and know-how to deploy these methods with clinical, commercial and legal confidence, enabling a new standard of care and the commercial models that come with it.